Makary Resigns, Adding Fresh Uncertainty to the FDA’s AI and Device Agenda
The reported resignation of FDA Commissioner Makary, with Diamantas named acting commissioner, introduces new uncertainty at a moment when the agency is setting the tone for AI device oversight. Leadership turnover could affect everything from review priorities to the pace of policy clarity for digital health companies.
Leadership changes at the FDA matter most when the agency is in the middle of defining a new technology category, and that is exactly the situation with healthcare AI. Recent clearances and high-profile debates suggest the agency is trying to balance innovation with safety, but any transition at the top can slow decision-making or shift emphasis toward caution.
For AI developers, the practical issue is predictability. Companies building clinical algorithms, monitoring systems, and decision-support tools need to understand how the agency interprets evidence, risk, and intended use. If leadership changes alter those expectations, product teams may face delays or be forced to rework regulatory strategies already in motion.
The resignation also lands in a politically sensitive environment. AI in healthcare is no longer framed simply as a technical challenge; it is increasingly part of a wider argument about oversight, fraud, patient protection, and administrative burden. Acting leadership may therefore be under pressure to signal continuity, even if policy direction evolves behind the scenes.
In the short term, the market may read this as a pause rather than a reversal. But the longer the agency takes to provide stable guidance on AI devices, the more companies will lean on conservative claims, narrower indications, and heavier post-market monitoring. That may slow innovation, but it could also produce safer products and cleaner evidence.